CC
TXMD icon

Carlson Capital’s TherapeuticsMD TXMD Stock Holding History

Carlson Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,996
Closed -$742K – 236
2020
Q1 		$742K Sell
13,996
-1,456
-9% -$144K 0.02% 179
2019
Q4 		$1.87M Buy
+15,452
New +$2.22M 0.03% 200
2019
Q3 		– Sell
-15,700
Closed -$2.04M – 279
2019
Q2 		$2.04M Buy
15,700
+14,173
+928% +$2.54M 0.03% 231
2019
Q1 		$372K Buy
+1,527
New +$404K 0.01% 238

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carlson Capital's TXMD Position: Q2 2020 in Review

Carlson Capital sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 13,996 shares — an estimated $742K sold.

Carlson Capital first reported a position in TXMD in Q1 2019 and held it in 4 quarters. The position peaked at $2.04M in Q2 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

  • Carlson Capital reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
  • Carlson Capital sold 13,996 TherapeuticsMD shares in Q2 2020, an estimated $742K.
  • Carlson Capital first reported a position in TherapeuticsMD in Q1 2019 and held it in 4 quarters.
  • Carlson Capital's TherapeuticsMD position peaked at $2.04M in Q2 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Carlson Capital's 13F filing for Q2 2020, filed 14 Aug 2020.